25
Participants
Start Date
October 4, 2021
Primary Completion Date
July 11, 2023
Study Completion Date
April 1, 2024
AGEN1777
An immunoglobulin gamma (IgG1) antibody
a PD-1 inhibitor
Anti-programmed cell death protein 1 (Anti-PD-1) antibody monoclonal antibody
University of Cincinnati Cancer Center, Cincinnati
Local Institution - 024, Southfield
Local Institution - 165, Grand Rapids
START Midwest, Grand Rapids
Local Institution - 164, Dallas
Mary Crowley Cancer Research, Dallas
MD Anderson Cancer Center Thoracic-Head & Neck Med Onc, Houston
Providence Cancer Institute, Portland
Local Institution - 072, Cincinnati
Lifespan Cancer Institute, Providence
Local Institution - 0001, Providence
Lead Sponsor
Agenus Inc.
INDUSTRY